Company Filing History:
Years Active: 2020
Title: Ian Tomlinson: Innovator in Toxicity Risk Assessment
Introduction: Ian Tomlinson is a notable inventor based in Oxford, GB, recognized for his significant contribution to the field of pharmacogenetics through a unique patent. With a focus on understanding the risk of toxicity associated with the chemotherapy drug 5-fluorouracil (FU), Tomlinson's work has the potential to improve patient outcomes significantly.
Latest Patents: Ian Tomlinson holds one patent titled "Method of determining risk of 5-fluorouracil toxicity." This invention provides an assay useful in predicting an individual's risk of developing toxicity when administered 5-fluorouracil. The assay screens subjects for the presence of specific TYMS and DPYD polymorphisms, where the detection of these polymorphisms indicates an increased risk of developing FU toxicity, while a negative result suggests a decreased risk. This innovation represents a step forward in personalized medicine, allowing for tailored therapeutic approaches.
Career Highlights: Tomlinson is affiliated with Oxford University Innovation Limited, a company that focuses on translating innovative research from the university into practical applications. His career has been marked by a commitment to advancing the understanding of drug metabolism and improving treatment protocols for patients receiving chemotherapy.
Collaborations: Throughout his career, Ian has collaborated with esteemed colleagues such as David Kerr and Dan Rosmarin. These partnerships have facilitated the sharing of knowledge and expertise, fostering advancements in the fields of oncology and pharmacogenetics.
Conclusion: Ian Tomlinson's invention regarding the risk assessment of 5-fluorouracil toxicity highlights the importance of innovation in medical science. By identifying genetic markers that influence drug response, his work paves the way for safer and more effective cancer treatments, demonstrating the profound impact that dedicated inventors can have in enhancing patient care and treatment outcomes.